Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.

You may also be interested in...



Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

Deals Of The Week: Sanofi/Genfar, Janssen/Astellas, Evotec/Bayer

It was an important week for Celgene, which made two cancer deals while producing data that help validate its $2.9 billion buyout of Abraxane.

VentiRx Pharmaceuticals Inc.

VentiRx Pharmaceuticals Inc. has been working since 2007 to develop TLR8 agonists for allergic rhinitis and cancer, while considering how they might also be used in other indications. The company reported positive data from Phase I clinical trials in both areas within the past year, but has recently decided to move forward in cancer only.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS073437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel